Category

Cancer

Cannabidiol induces programmed cell death in breast cancer cells by coordinating the cross-talk between apoptosis and autophagy.

By | Breast Cancer, Cancer

Authors: Ashutosh Shrivastava, Paula M. Kuzontkoski, Jerome E. Groopman, Anil Prasad
Molecular Cancer Therapeutics, July 2011

Cannabidiol (CBD), a major nonpsychoactive constituent of cannabis, is considered an antineoplastic agent on the basis of its in vitro and in vivo activity against tumor cells. However, the exact molecular mechanism through which CBD mediates this activity is yet to be elucida…

Read More

Spontaneous regression of septum pellucidum/forniceal pilocytic astrocytomas–possible role of Cannabis inhalation.

By | Brain Cancer, Cancer

Authors: Mansoor Foroughi, Glenda Hendson, Michael A. Sargent, Paul Steinbok
Child’s Nervous System, DATE

INTRODUCTION: Spontaneous regression of pilocytic astrocytoma after incomplete resection is well recognized, especially for cerebellar and optic pathway tumors, and tumors associated with Neurofibromatosis type-1 (NF1). The purpose of this report is to document spontaneous reg…

Read More

A combined preclinical therapy of cannabinoids and temozolomide against glioma.

By | Brain Cancer, Cancer

Authors: Sofía Torres, Mar Lorente, Fátima Rodríguez-Fornés, Sonia Hernández-Tiedra, et al
Molecular Cancer Therapeutics, January 2011

Glioblastoma multiforme (GBM) is highly resistant to current anticancer treatments, which makes it crucial to find new therapeutic strategies aimed at improving the poor prognosis of patients suffering from this disease. Δ(9)-Tetrahydrocannabinol (THC), the major active ingred…

Read More

Cannabinoids reduce ErbB2-driven breast cancer progression through Akt inhibition.

By | Breast Cancer, Cancer

Authors: María M Caffarel, Clara Andradas, Emilia Mira, Eduardo Pérez-Gómez, Camilla Cerutti, et al
Molecular Cancer, 22 July 2010

BACKGROUND: ErbB2-positive breast cancer is characterized by highly aggressive phenotypes and reduced responsiveness to standard therapies. Although specific ErbB2-targeted therapies have been designed, only a small percentage of patients respond to these treatments and most o…

Read More

Cannabidiol enhances the inhibitory effects of delta9-tetrahydrocannabinol on human glioblastoma cell proliferation and survival.

By | Brain Cancer, Cancer

Authors: Jahan P. Marcu, Rigel T. Christian, Darryl Lau, Anne J. Zielinski, Maxx P. Horowitz, et al
Molecular Cancer Therapeutics, January 2010

The cannabinoid 1 (CB(1)) and cannabinoid 2 (CB(2)) receptor agonist Delta(9)-tetrahydrocannabinol (THC) has been shown to be a broad-range inhibitor of cancer in culture and in vivo, and is currently being used in a clinical trial for the treatment of glioblastoma. It has bee…

Read More

Synthetic cannabinoid receptor agonists inhibit tumor growth and metastasis of breast cancer.

By | Breast Cancer, Cancer, Lung Cancer

Authors: Zahida Qamri, Anju Preet, Mohd W. Nasser, Caroline E. Bass, Gustavo Leone, et al
Molecular Cancer Therapeutics, November 2009

Cannabinoids have been reported to possess antitumorogenic activity. Not much is known, however, about the effects and mechanism of action of synthetic nonpsychotic cannabinoids on breast cancer growth and metastasis. We have shown that the cannabinoid receptors CB1 and CB2 ar…

Read More

Inhibition of human tumour prostate PC-3 cell growth by cannabinoids R(+)-Methanandamide and JWH-015: involvement of CB2.

By | Cancer, Prostatic Cancer, Research Articles

Authors: N. Olea-Herrero, D. Vara, S. Malagarie-Cazenave, I. Díaz-Laviada
British Journal of Cancer, 15 September 2009

BACKGROUND: We have previously shown that cannabinoids induce growth inhibition and apoptosis in prostate cancer PC-3 cells, which express high levels of cannabinoid receptor types 1 and 2 (CB(1) and CB(2)). In this study, we investigated the role of CB(2) receptor in the anti…

Read More

Cannabinoid receptors in human astroglial tumors.

By | Brain Cancer, Cancer

Authors: Janka Held‐Feindt, Lutz Dörner, Gülcan Sahan,H. Maximilian Mehdorn, Rolf Mentlein
Journal of Neurochemistry, August 2008

In animal models, cannabinoids are reported to inhibit the growth of tumors, including gliomas. These effects have been claimed to be mediated via cannabinoid receptors 1 and 2 (CB1, CB2). To elucidate a possible relevance for treatment of human gliomas, we investigated recept…

Read More

Cannabinoids for cancer treatment: progress and promise.

By | Brain Cancer, Breast Cancer, Cancer, Lymphoma, Pancreatic Cancer, Prostatic Cancer, Skin Cancer

Authors: Sami Sarfaraz, Vaqar M. Adhami, Deeba N. Syed, Farrukh Afaq, Hasan Mukhtar
Cancer Research, 15 January 2008

Cannabinoids are a class of pharmacologic compounds that offer potential applications as antitumor drugs, based on the ability of some members of this class to limit inflammation, cell proliferation, and cell survival. In particular, emerging evidence suggests that agonists of…

Read More

Cannabidiol as a novel inhibitor of Id-1 gene expression in aggressive breast cancer cells.

By | Breast Cancer, Cancer

Authors: Sean D. McAllister, Rigel T. Christian, Maxx P. Horowitz, Amaia Garcia, Pierre-Yves Desprez
Molecular Cancer Therapeutics, November 2007

Invasion and metastasis of aggressive breast cancer cells is the final and fatal step during cancer progression, and is the least understood genetically. Clinically, there are still limited therapeutic interventions for aggressive and metastatic breast cancers available. Clear…

Read More